Status:
COMPLETED
Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
Lead Sponsor:
Stanford University
Conditions:
Brain Cancer
Neoplasm Metastasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined. This study investigates if increasin...
Detailed Description
Brain metastases are the most common intracranial tumors and occur in approximately 25% of patients with cancer. In the US, approximately 170,000 cancer patients a year are diagnosed with brain metast...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA
- Age 18 years and older
- Pathologically-proven solid tumor malignancy
- 1 to 4 brain metastases, one of which is 4.2 to 33.5 cm³.
- Prior surgery or SRS is allowed as long as the target metastatic lesion in this study has not previously been treated with SRS.
- Prior cytotoxic systemic therapy must be completed ≥ 5 days prior to radiosurgery. No concurrent cytotoxic systemic therapy along with SRS. Cytotoxic systemic therapy to start ≥ 5 days after the completion of SRS.
- Life expectancy of ≥ 12 weeks.
- Ability to understand and the willingness to sign a written informed consent.
- EXCLUSION CRITERIA
- Previously treated with whole brain irradiation
- Target metastatic lesion previously been treated with SRS.
- \> 4 total brain metastases at the time of initial evaluation.
- Pregnant
- Unable to give informed consent.
Exclusion
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00928226
Start Date
April 1 2009
End Date
December 1 2019
Last Update
January 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305